Rice Hall James & Associates LLC cut its stake in Juniper Pharmaceuticals Inc. (NASDAQ:JNP) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,806 shares of the specialty pharmaceutical company’s stock after selling 288 shares during the period. Rice Hall James & Associates LLC’s holdings in Juniper Pharmaceuticals were worth $251,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Bellevue Group AG bought a new position in shares of Juniper Pharmaceuticals during the first quarter valued at about $331,000. Renaissance Technologies LLC increased its position in shares of Juniper Pharmaceuticals by 8.2% in the first quarter. Renaissance Technologies LLC now owns 202,900 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 15,300 shares during the period. Finally, Spark Investment Management LLC increased its position in shares of Juniper Pharmaceuticals by 16.6% in the first quarter. Spark Investment Management LLC now owns 53,400 shares of the specialty pharmaceutical company’s stock valued at $352,000 after buying an additional 7,600 shares during the period. 33.61% of the stock is currently owned by institutional investors and hedge funds.
Juniper Pharmaceuticals Inc. (NASDAQ:JNP) traded down 1.07% on Tuesday, reaching $5.55. 38,950 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $5.71 and its 200 day moving average is $6.77. The company’s market cap is $60.18 million. Juniper Pharmaceuticals Inc. has a 52 week low of $4.30 and a 52 week high of $12.75.
Juniper Pharmaceuticals (NASDAQ:JNP) last issued its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.08. Juniper Pharmaceuticals had a negative return on equity of 6.39% and a negative net margin of 5.81%. On average, equities analysts anticipate that Juniper Pharmaceuticals Inc. will post ($0.39) earnings per share for the current year.
Several research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, July 25th. HC Wainwright downgraded shares of Juniper Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $6.75 price target on the stock. in a research report on Friday, August 19th. Northland Securities downgraded shares of Juniper Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Roth Capital set a $16.50 price target on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, August 21st. Finally, TheStreet downgraded shares of Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 12th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $11.50.
In other Juniper Pharmaceuticals news, insider Alicia Secor bought 5,000 shares of the firm’s stock in a transaction on Thursday, August 25th. The shares were purchased at an average price of $5.75 per share, for a total transaction of $28,750.00. Following the completion of the transaction, the insider now directly owns 5,000 shares in the company, valued at approximately $28,750. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James A. Geraghty bought 7,000 shares of the firm’s stock in a transaction on Tuesday, August 23rd. The stock was acquired at an average price of $5.96 per share, for a total transaction of $41,720.00. Following the transaction, the director now owns 58,216 shares of the company’s stock, valued at $346,967.36. The disclosure for this purchase can be found here. 11.60% of the stock is owned by corporate insiders.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc, formerly Columbia Laboratories, Inc, is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE.
Want to see what other hedge funds are holding JNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juniper Pharmaceuticals Inc. (NASDAQ:JNP).
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.